Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Champions Oncology (CSBR) Non Operating Income (2016 - 2025)

Historic Non Operating Income for Champions Oncology (CSBR) over the last 16 years, with Q4 2025 value amounting to $70000.0.

  • Champions Oncology's Non Operating Income rose 90000.0% to $70000.0 in Q4 2025 from the same period last year, while for Oct 2025 it was $207000.0, marking a year-over-year increase of 3708.61%. This contributed to the annual value of $73000.0 for FY2025, which is 5208.33% up from last year.
  • According to the latest figures from Q4 2025, Champions Oncology's Non Operating Income is $70000.0, which was up 90000.0% from $75000.0 recorded in Q3 2025.
  • Champions Oncology's Non Operating Income's 5-year high stood at $81000.0 during Q2 2024, with a 5-year trough of -$105000.0 in Q4 2023.
  • Over the past 5 years, Champions Oncology's median Non Operating Income value was $10500.0 (recorded in 2021), while the average stood at $11550.0.
  • In the last 5 years, Champions Oncology's Non Operating Income plummeted by 106666.67% in 2023 and then skyrocketed by 140000.0% in 2025.
  • Quarter analysis of 5 years shows Champions Oncology's Non Operating Income stood at $26000.0 in 2021, then crashed by 134.62% to -$9000.0 in 2022, then crashed by 1066.67% to -$105000.0 in 2023, then soared by 106.67% to $7000.0 in 2024, then skyrocketed by 900.0% to $70000.0 in 2025.
  • Its last three reported values are $70000.0 in Q4 2025, $75000.0 for Q3 2025, and $43000.0 during Q2 2025.